(January 6, 2017, 2:28 PM EST) -- PHILADELPHIA — A Pennsylvania federal judge on Jan. 4 dismissed claims by a generic drug manufacturer that Indivior Inc. engaged in anti-competitive behavior by delaying the introduction of a generic version of the opioid treatment drug Suboxone (buprenorphine and naloxone) but allowed the plaintiff to refile its false advertising claims (In Re: Suboxone [Buprenorphine Hydrochloride and Naloxone] Antitrust Litigation, MDL Docket No. 2445, No. 13-md-2445, Amneal Pharmaceuticals LLC v. Indivior Inc., No. 16-563, E.D. Pa.)....